Blog

New Science can deliver accessible, affordable, and transformative patient outcomes when built on well-defined outgrowth strategies that access emerging technologies.

“CPV is a broader concept because it gives you a more holistic picture of overall product performance over a period of time. While both APR and CPV give you an indication of product performance, the current situation in most companies is that they remain disconnected".

Roche/Genentech eliminated 50% of the non-value-added paper-based tasks employees were forced to perform and reallocated resources to prioritize innovation.

Digitalization and the Pharma 4.0 vision appeals to young generation engineers from ‘career development’ and ‘cultural engagement’ perspectives.

The evolution from compliance to a proactive learning system focused on patient quality outcomes involves overcoming several barriers, says FDA.

Faster innovation and time to market are top priorities for CDMOs. Being a digital-first organization gives Theragent a substantial competitive advantage.

CSA is achievable under current regulation. If you’re following these 3 core CSV principles, odds are you’re already aligned with the new CSA methodology.

We write about how we helped a company in accelerating the time-to-market of a drug product using a Quality by Design (QbD) framework

ROI study reveals how much time and money customers save by digitizing corporate validation processes. Watch the webinar (link in post).

When manufacturers rely on paper-based logbooks, they expose themselves to human errors, poor data integrity, and a host of compliance risks.